EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An expanded role for single-cell chemical genomics profiling in drug discovery

Adeya Wyatt, Kevin Hoffer-Hawlik, Ross M Giglio, Elham Azizi, José L McFaline-Figueroa iD

Biochemical Journal · 04.02.2026 · 483 (2) · 211-228

DOI: 10.1042/bcj20253273 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Journal, online erschienen am 21.01.2026. Verfasst von Adeya Wyatt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, New York, NY 10027, U.S.A. Hauptthemen laut MEDLINE: Drug Discovery, Genomics, Single-Cell Analysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of single-cell genomics into the chemical genetics paradigm is reshaping how researchers profile drug activity, prioritize lead candidates, and uncover new therapeutic opportunities. Traditional chemical genetic approaches, though instrumental in linking compounds to cellular phenotypes, often rely on bulk measurements that obscure important cellular heterogeneity and limit insight into mechanisms of action. By contrast, single-cell technologies offer a transformative view of how compounds influence diverse cell types and states, capturing nuanced molecular responses that further our understanding of efficacy, resistance, and polypharmacology. From cancer to neurodegenerative disorders and other disease contexts, single-cell chemical profiling enables a more precise annotation of drug-induced effects, revealing differential responses across cellular subpopulations. These methods help identify both beneficial and adverse outcomes that may not be readily predicted by a compound’s structure or known targets, enhancing preclinical prioritization and supporting rational drug repurposing strategies. As these technologies mature, advances in multiplexing, multimodal profiling, and computational analysis are expanding their scalability and applicability to increasingly complex models. The resulting data-rich assays are poised to bridge critical gaps between compound screening and clinical relevance. This review highlights the evolution of chemical genomics toward single-cell resolution and outlines emerging opportunities to leverage these methods throughout the drug discovery pipeline, from early preclinical prioritization to late-stage repurposing, ultimately accelerating the development of safer, more effective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryGenomicsSingle-Cell AnalysisHumansAnimals

Stichwörter der Autor:innen

CRISPRdrug discovery and designfunctional genomicshigh-throughput screeningpharmacogenomics

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Columbia University, New York, NY 10027, U.S.A.
  • Irving Institute for Cancer Dynamics, Columbia University, New York, NY 10027, U.S.A.
  • Department of Molecular Pharmacology and Therapeutics, Columbia University Medical Center, New York, NY 10032, U.S.A.
  • Department of Computer Science, Columbia University, New York, NY 10027, U.S.A.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, U.S.A.
  • Data Science Institute, Columbia University, New York, NY 10027, U.S.A.

ORCID-Profile: José L McFaline-Figueroa

Förderung

  • NIH HHS
  • Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation
  • NHGRI NIH HHS
  • Allen Family Philanthropies - Paul G. Allen Frontiers Group
  • NSF
  • National Science Foundation
  • NIH
  • Allen Family Philanthropies – Paul G. Allen Frontiers Group

Zitieren

APA

Wyatt, A., Hoffer-Hawlik, K., Giglio, R. M., Azizi, E., & McFaline-Figueroa, J. L. (2026). An expanded role for single-cell chemical genomics profiling in drug discovery. Biochemical Journal, 483(2), 211-228. https://doi.org/10.1042/bcj20253273

Vancouver

Wyatt A, Hoffer-Hawlik K, Giglio RM, Azizi E, McFaline-Figueroa JL. An expanded role for single-cell chemical genomics profiling in drug discovery. Biochemical Journal. 2026;483(2):211-228. doi:10.1042/bcj20253273

BibTeX
@article{Wyatt2026,
  author = {Wyatt, Adeya and Hoffer-Hawlik, Kevin and Giglio, Ross M and Azizi, Elham and McFaline-Figueroa, José L},
  title = {An expanded role for single-cell chemical genomics profiling in drug discovery},
  journal = {Biochemical Journal},
  year = {2026},
  volume = {483},
  number = {2},
  pages = {211--228},
  doi = {10.1042/bcj20253273}
}
Kostenlos starten →